• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    TenX Keane Acquisition Announces Extension of the Deadline for an Initial Business Combination

    10/18/23 4:00:00 PM ET
    $TENK
    Blank Checks
    Finance
    Get the next $TENK alert in real time by email

    New York, NY, Oct. 18, 2023 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (the "Company") (NASDAQ:TENKU) today announced that, in order to extend the date by which the Company must complete its initial business combination from October 18, 2023 to January 18, 2024, the Company has deposited into its trust account (the "Trust Account") an aggregate of $660,000 (the "Extension Fee"), representing $0.10 per public share of the Company. The payment for such Extension Fee was made by 10XYZ Holdings LP, the sponsor of the Company (the "Sponsor"), which was evidenced by an unsecured promissory note issued by the Company to the Sponsor.

    This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    About TenX Keane Acquisition

    TenX Keane Acquisition is a blank check company, also commonly referred to as a special purpose acquisition company, or SPAC, formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities.

    Forward-Looking Statements

    This press release contains statements that constitute "forward-looking statements," including with respect to the separation and trading of the Company's securities and search for an initial business combination. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of TenX Keane Acquisition, including those set forth in the Risk Factors section of TenX Keane Acquisition's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q filed with the SEC. Copies are available on the SEC's website, www.sec.gov. TenX Keane Acquisition undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

    Contact Information:

    Taylor Zhang

    Chief Financial Officer

    Email: [email protected]

    Tel: (347) 627-0058



    Primary Logo

    Get the next $TENK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TENK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TENK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update

      TenX Keane shareholders voted to approve the previously announced merger with Citius Oncology at an extraordinary general meeting held on August 2, 2024 Post-merger company expected to trade on Nasdaq as Citius Oncology, Inc. (CTOR) New York, NY, Aug. 09, 2024 (GLOBE NEWSWIRE) -- On August 7, 2024, TenX Keane Acquisition (NASDAQ:TENKU, TENK, TENKR))) ("TenX"), a publicly traded special purpose acquisition company, was notified by The Nasdaq Stock Market that trading in TenX's securities had been halted for "additional information requested" from the company. The trading halt was imposed following volatility in the trading price and volume of TenX's securities on Wednesday, August 7, 202

      8/9/24 7:30:00 AM ET
      $CTXR
      $TENK
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Blank Checks
      Finance
    • TenX Keane Acquisition Shareholders Approve Previously Announced Merger to Form Citius Oncology, Inc., a Publicly Listed Subsidiary of Citius Pharmaceuticals

      TenX Keane shareholders voted to approve the previously announced merger with Citius Oncology at an extraordinary general meeting held on August 2, 2024 Post-merger company expected to trade on Nasdaq as Citius Oncology, Inc. Transaction expected to support commercialization of LYMPHIR, if approved, and exploration of additional oncology assets New York, NY, Aug. 05, 2024 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (NASDAQ:TENKU, TENK, TENKR))) (the "TenX"), a publicly traded special purpose acquisition company, today announced that on August 2, 2024, at the extraordinary general meeting, its shareholders voted to approve the previously announced business combination with the wholly own

      8/5/24 8:00:00 AM ET
      $CTXR
      $TENK
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Blank Checks
      Finance
    • Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc.

      Citius Pharmaceuticals to receive 65.6 million shares of TenX Keane, which will be renamed Citius Oncology, Inc. Citius Pharmaceuticals to retain approximately 90% majority control post transaction    Post-merger company expected to trade on Nasdaq as Citius Oncology, Inc. Transaction expected to support commercialization of LYMPHIR, if approved, and exploration of additional oncology assets CRANFORD, N.J., Aug. 5, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that shareholders of TenX Keane

      8/5/24 8:00:00 AM ET
      $CTXR
      $TENK
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Blank Checks
      Finance

    $TENK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Dutia Suren G

      4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

      8/14/24 6:29:05 PM ET
      $TENK
      Blank Checks
      Finance
    • SEC Form 4 filed by Director Holubiak Myron Z

      4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

      8/14/24 6:28:37 PM ET
      $TENK
      Blank Checks
      Finance
    • SEC Form 4 filed by Chief Medical Officer Czuczman Myron

      4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

      8/14/24 6:28:05 PM ET
      $TENK
      Blank Checks
      Finance

    $TENK
    SEC Filings

    See more
    • SEC Form 25-NSE filed by TenX Keane Acquisition

      25-NSE - CITIUS ONCOLOGY, INC. (0001851484) (Subject)

      8/13/24 4:33:39 PM ET
      $TENK
      Blank Checks
      Finance
    • SEC Form 10-Q filed by TenX Keane Acquisition

      10-Q - CITIUS ONCOLOGY, INC. (0001851484) (Filer)

      8/9/24 4:22:23 PM ET
      $TENK
      Blank Checks
      Finance
    • TenX Keane Acquisition filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

      8-K - TenX Keane Acquisition (0001851484) (Filer)

      8/2/24 8:45:17 PM ET
      $TENK
      Blank Checks
      Finance

    $TENK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by TenX Keane Acquisition

      SC 13D/A - CITIUS ONCOLOGY, INC. (0001851484) (Subject)

      8/15/24 12:53:48 PM ET
      $TENK
      Blank Checks
      Finance
    • SEC Form SC 13G/A filed by TenX Keane Acquisition (Amendment)

      SC 13G/A - TenX Keane Acquisition (0001851484) (Subject)

      3/7/24 4:06:26 PM ET
      $TENK
      Blank Checks
      Finance
    • SEC Form SC 13G filed by TenX Keane Acquisition

      SC 13G - TenX Keane Acquisition (0001851484) (Subject)

      2/13/24 8:09:57 PM ET
      $TENK
      Blank Checks
      Finance